A new CHOP study found only one in three eligible patients took Beyfortus when the medication that protects against severe ...

AstraZeneca’s AZN second-quarter 2025 core earnings of $1.09 per American depositary share (ADS) came in line with the Zacks ...

The deal seeks to strengthen the drugmaker’s portfolio of respiratory vaccines and help it move on from pipeline setbacks.

A large-scale real-world study in the USA has reinforced the effectiveness of Beyfortus (nirsevimab-alip), the respiratory ...

The largest US real-world study of BEYFORTUS (nirsevimab-alip) 50mg and 100mg Injection successfully met both of its co-primary endpoints, demonstrating that BEYFORTUS provides protection for babies ...

Parental trust in clinicians drove RSV vaccine uptake, while confusion and limited access to reliable information hindered ...

When Beyfortus was approved over the summer, AstraZeneca and Sanofi, the two companies that manufacture the drug, said it would be available for babies in time for RSV season this year.

That means that if pediatricians have only VFC-supplied Beyfortus in stock and need a dose for a baby who is not eligible for VFC coverage, they could use the dose, so long as they replace it.

This new drug, Beyfortus, will not only help lift some of the stress doctors deal with, but also keep hospitalizations down. It would be given to babies that come through hospitals, and would ...

Sanofi is shipping Beyfortus (nirsevimab) starting in early Q3 to ensure broad availability well ahead of the 2025-2026 respiratory syncytial virus (RSV) season, which typically starts in November ...

New Beyfortus data featured at IDWeek reinforce real-world effectiveness against RSV disease and hospitalization in infants Paris, October 9, 2024. Sanofi advances its ambition to protect all ...